AbbVie Inc.
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
(Unaudited)
(in millions, except per share data) | Quarter Ended December 31, 2023 | Full-Year Ended December 31, 2023 | |||||||||||||||||||||||||||||||||
Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range | Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range | ||||||||||||||||||||||||||||||||
Low | High | Low | High | ||||||||||||||||||||||||||||||||
Previously announced guidance excluding Q4 2023 acquired IPR&D and milestones expense | $ | — | $ | 2.87 | $ | 2.91 | $ | 496 | $ | 11.19 | $ | 11.23 | |||||||||||||||||||||||
Q4 2023 acquired IPR&D and milestones expense | 282 | (0.15) | (0.15) | 282 | (0.15) | (0.15) | |||||||||||||||||||||||||||||
Guidance including Q4 2023 acquired IPR&D and milestones expense | $ | 282 | $ | 2.72 | $ | 2.76 | $ | 778 | $ | 11.04 | $ | 11.08 |
1